Septerna (NASDAQ:SEPN) Price Target Raised to $62.00 at JonesTrading

Septerna (NASDAQ:SEPN) had its price target hoisted by stock analysts at JonesTrading from $43.00 to $62.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. JonesTrading’s price objective would suggest a potential upside of 36.64% from the company’s previous close.

Several other research analysts have also weighed in on the stock. Truist Financial increased their price objective on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Guggenheim lifted their target price on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday. Raymond James Financial reiterated a “strong-buy” rating and issued a $49.00 price target on shares of Septerna in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Finally, HC Wainwright lifted their price objective on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $51.33.

Septerna Trading Down 5.8%

Shares of NASDAQ SEPN traded down $2.82 during trading on Thursday, reaching $45.37. The company had a trading volume of 478,258 shares, compared to its average volume of 358,741. The stock has a market capitalization of $2.12 billion, a PE ratio of -84.08 and a beta of 2.29. Septerna has a twelve month low of $10.74 and a twelve month high of $51.10. The stock has a 50-day moving average price of $35.29 and a two-hundred day moving average price of $29.40.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.59%. The business had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. On average, sell-side analysts predict that Septerna will post -1.59 EPS for the current year.

Insiders Place Their Bets

In other Septerna news, insider Samira Shaikhly sold 11,798 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at $23,837.58. This represents a 93.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Daniel D. Long sold 15,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at $3,423,590.12. This trade represents a 13.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 47,828 shares of company stock worth $1,584,314 over the last quarter. 5.80% of the stock is currently owned by company insiders.

Institutional Trading of Septerna

Several hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP increased its position in Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after acquiring an additional 282,585 shares during the period. Rhumbline Advisers grew its position in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after purchasing an additional 3,323 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after purchasing an additional 78,316 shares during the period. JPMorgan Chase & Co. raised its position in shares of Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after buying an additional 1,315 shares during the last quarter. Finally, CW Advisors LLC acquired a new position in shares of Septerna during the second quarter valued at about $133,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.